Kronos Bio Inc (KRON) USD0.001
Sell:$0.87Buy:$0.89
$0.00
(0.28%)
- This stock can be held in a
Stocks and Shares ISA$0.00
(0.28%)$0.00
(0.28%)Company Information
About this company
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Its product candidates include KB-9558 and KB-7898. KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN, is in preclinical development for the treatment of multiple myeloma and human papillomavirus (HPV)-driven tumors. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. KB-7898 is a p300 KAT inhibitor for the treatment of Sjogren’s disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca.
Key people
Key facts
- EPICKRON
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS50107A1043
- Market cap$54.11m
- Employees8
- Shares in issue60.97m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.